Reading of 1 min 
Natac Natural Ingredients (NAT), a biotechnology company specializing in the sustainable production of botanical extracts and omega-3 oils, has released its financial update as of October 15, 2025. By that date, the company achieved revenues of €31.88 million and a normalized EBITDA of €14.6 million, representing increases of 95% and 169%, respectively, compared to the first half of the year.
As noted in its Integrated Report for the first half, this period was characterized by a normalization of activity levels, following an atypical 2024 in which orders traditionally placed in the second half of the year were concentrated between January and June.
“Unlike what happened in 2024, this year is progressing in line with normal market cycles and our expectations, confirming sustained organic growth across all business lines,” explained Antonio Delgado, CEO of Natac.
As of October 15, the company had pending orders to be delivered before year-end valued at €15.16 million. This figure, together with the revenues already recorded and the activity expected through December, supports the company’s full-year outlook. Specifically, Natac expects to close 2025 with sales exceeding €50 million and a normalized EBITDA above €20 million.
